ArticleClinical and experimental reproductive medicine2026
Does coenzyme Q10 protect testicular function and spermatogenesis in rats receiving levofloxacin-containing therapy?
Article in Clinical and experimental reproductive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveLevofloxacin (LVFX), a fluoroquinolone antibiotic, is used in the treatment of urogenital tract diseases affecting the reproductive system. This study aimed to examine the protective effects of coenzyme Q10 (CoQ10) against LVFX-induced side effects using stereological methods.
methodsEighty rats were divided into eight groups: control (distilled water), CoQ10 (10 mg/kg/day), and low dose (25 mg/kg/day), medium dose (50 mg/kg/day), and high dose (100 mg/kg/day) of LVFX (low dose [LD]-LVFX, medium dose [MD]-LVFX, and high dose [HD]-LVFX) with or without CoQ10 administration. Treatments were performed daily for 4 weeks. Sperm parameters, serum testosterone levels, testicular oxidative stress markers, and testicular histology were evaluated.
resultsSperm count, motility, normal morphology, and viability, as well as serum testosterone levels, were reduced, while malondialdehyde concentrations increased in MD-LVFX and HD-LVFX treated animals compared to controls. MD-LVFX and HD-LVFX treatments produced a 6% to 56% reduction in the volumes, lengths, and diameters of seminiferous tubules and their epithelium, whereas the interstitial tissue volume increased by 43% to 53% in these groups. The numbers of spermatogonia, spermatocytes, spermatids, Sertoli cells, and Leydig cells were reduced by 23% to 76% in animals treated with MD-LVFX and HD-LVFX compared to controls. Notably, all changes observed in the rats receiving CoQ10 were similar to those in the control group, and although most parameters decreased in animals that received LD-LVFX, the differences were not statistically significant relative to controls.
conclusionLVFX treatment for 28 days, regardless of dose, adversely affected sperm parameters and testicular tissue. CoQ10 exhibited a protective effect by mitigating the structural and functional impairments induced by LVFX.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.